Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00635284 · ClinicalTrials.gov registry record · Phase 1

ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies

A Phase 1 study of Solid Tumors, sponsored by Celgene.

Completed
Registry status
Phase 1
Development phase
27
Enrollment target
2
Study locations

NCT00635284 is a Phase 1 study of Solid Tumors that has completed, run by Celgene. The registered enrollment target is 27 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00635284, a Phase 1 study of Solid Tumors, has completed, sponsored by Celgene.

COMPLETED
Registry status
Phase 1
Development phase
27 participants
Enrollment target
2
Study locations

Study Summary

To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009 given weekly; to characterize the toxicities of ABI-009; and to determine the pharmacokinetic parameters for ABI-009 when given on a weekly schedule.

Conditions Studied

Solid Tumors

Interventions

  • DRUG ABI-009

Study Locations (2)

California

  • Sarcoma Oncology Center - Santa Monica

Texas

  • University of Texas M.D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2007-12-01
Est. Completion 2011-06-01
Phase Phase 1

Sponsor

Celgene

308 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00635284

The ClinicalTrials.gov registry entry for NCT00635284 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (90% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ABI-009 is the first listed.

NCT00635284 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.

Frequently Asked Questions

What is clinical trial NCT00635284 about?

NCT00635284 is a clinical study titled "ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies". To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009 given weekly; to characterize the toxicities of ABI-009; and to determine the pharmacokinetic parameters for ABI-009 when given on a weekly schedule.

What is the current status of trial NCT00635284?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2007-12-01. Estimated completion is 2011-06-01.

What conditions does trial NCT00635284 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT00635284?

The interventions under investigation include: ABI-009 (DRUG).

Who is sponsoring clinical trial NCT00635284?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00635284 being conducted?

This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.